5D·

More info: California lawmakers want to cut Medicare coverage for GLP-1s

$NOVO B (+0,2%)
$HIMS (+1,18%)
$LLY (+0,11%)
$UNH (+0,5%)

- Lawmakers propose cutting Wegovy and Zepbound from Medicaid to reduce $12 billion deficit

- Would save $680 million annually through 2029 if passed

Source: Bloomberg Law

Novo Nordisk is under investigation by the Spanish Ministry of Health for possible illegal advertising of its hit drug Wegovy. The authorities believe that an online campaign related to Novo could be classified as indirect advertising for a prescription drug, which is prohibited. The website is now offline. Shares fell as much as 2.8% in Copenhagen on Wednesday. (via Bloomberg)

16 Comentários

Aktienfox@Aktienfox

Very good, was just about to summarize it :), that's the way!

•

BamBamInvest@BamBamInvest

This is the way 👍

••

fund_commander123@fund_commander123

The planned cuts are bad news for $HIMS. This could lead to a loss of customers and revenue 👎

•

Lupo201@Lupo201

@fund_commander123 absolutely not! Top for Hims if it is enforced. The expensive original products will be taken out of the insurance and customers will be more likely to go for the cheaper Hims alternative

•

BamBamInvest@BamBamInvest

@Lupo201 @fund_commander123 That's how I see it too, $HIMS is trying to make treatments and medicines more affordable. As far as GLP1 is concerned, so far it has mainly been personalized, but when that comes, the question of drug price caps will probably come up again. But if people are not covered by Medicare, which is only available to certain people, or by private insurance, they will look for cheaper alternatives. This has enormous potential once the patents expire at the latest.

•

fund_commander123@fund_commander123

@Lupo201 yes, perhaps I should have read more than just the headline. You're right, of course. Then of course I'm all the happier for my $HIMS position 😅

•

Flyklmm@Flyklmm

❤️🚀

•

John@Doe

The market must have felt very good today...

•

BamBamInvest@BamBamInvest

@Doe I'm not sure if $HIMS is really losing trust here as an American company just because a European company is making claims and desperate to sell its products. Seems more like Robinhood vs Prince John to me 😂. I think the consumer likes what $HIMS is doing and the products should work, I'm curious to see how this develops.

•

MaxGPower@MaxGPower

Get out with a slight plus at €35 or hold the share? What do you think?

••

Lupo201@Lupo201

@MaxGPower $HIMS always hold, what kind of question is that anyway😅

•

Kate🦋@Iwamoto

Hello @BamBamInvest I discovered the health care etf in your portfolio by chance. I wanted to ask whether this is a short-term trade or a long-term position for you?

••

BamBamInvest@BamBamInvest

@Iwamoto is more short-term, like a cash position, because I think the sector has some catching up to do and has historically performed poorly. It could also perform well in a volatile phase. At least that's my assessment. ✌️

•

Kate🦋@Iwamoto

@BamBamInvest I absolutely agree with you that the sector, which is otherwise one of the stronger ones, will certainly make up the gap. That's why I've been thinking about investing in such a sector ETF for some time now, but haven't yet been able to decide which one 🙈

•

BamBamInvest@BamBamInvest

@Iwamoto In addition, the purchase is currently free of charge for me at flatex, which is why I chose it and feel relatively safe in the sector. The weight loss market will continue to grow strongly $UNH and $NOVO B will recover at some point. The chart, if it is meaningful for an ETF, also looks very good, we are moving sideways and are at the lower edge. (Simply put)

•

BamBamInvest@BamBamInvest

@Iwamoto do it, you can also do it in installments 😁

•